Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ann Pharm Fr. 2013 Mar;71(2):104-8. doi: 10.1016/j.pharma.2013.01.003. Epub 2013 Mar 1.

[Introduction to novel vaccine adjuvants and their role in influenza vaccination].

[Article in French]

Author information

  • 1Discovery R&D, Sanofi Pasteur, Campus Mérieux, 1541, avenue Marcel-Mérieux, 69280 Marcy-l'Étoile, France. Jean.Haensler@sanofipasteur.com

Abstract

New vaccine approaches based on subunit vaccines and on highly purified recombinant proteins use adjuvants to compensate for the loss of immunostimulatory components that are naturally present in whole cell vaccines. The development of adjuvanted influenza vaccines comprising squalene emulsion adjuvants effective against pandemic influenza strains highlights the contribution of novel adjuvants in increasing vaccine coverage by augmenting protection rates and by affording cross-strain protection and antigen dose-sparing. Nevertheless, the development of new adjuvants remains challenging in terms of quality and safety assurance and in terms of clinical and industrial development costs.

Copyright © 2013 Elsevier Masson SAS. All rights reserved.

PMID:
23537411
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Masson (France)
    Loading ...
    Write to the Help Desk